Increasing Transparency in Generic Drug Applications Act of 2022

United States117th CongressHR-7032House of Representatives
Updated: Mar 10, 2022

Summary

Increasing Transparency in Generic Drug Applications Act of 2022 This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

Latest companion bill action

S-4338: Increasing Transparency in Generic Drug Applications Act

Introduced in Senate

  1. Introduced in House

  2. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.